阿维菌素

• 常用名: 阿维菌素
• 英文名: Avermectin B1a
• CAS号: 65195-55-3
• 分子量: 873.077
• 密度: 1.2±0.1 g/cm3
• 沸点: 940.9±65.0 °C at 760 mmHg
• 分子式: C₄₈H₇₂O₁₄
• 熔点: 157-162ºC
• 闪点: 268.1±27.8 °C

阿维菌素用途

Avermectin B1a 是一种抗寄生虫剂，能够使线虫瘫痪。

阿维菌素名称

• 中文名: 阿维菌素
• 英文名: avermectin B1a
• 中文别名: 阿维菌素B1a | 阿巴汀

阿维菌素生物活性

• 描述: Avermectin B1a 是一种抗寄生虫剂,能够使线虫瘫痪。
• 相关类别:
  信号通路 >> 抗感染 >> 寄生物
  研究领域 >> 感染
• 体外研究: [3H] AVM B1a优先与来自大鼠脑的几个区域的突触膜结合。 [3H] AVM B1a与完整单层颗粒细胞的特异性结合随孵育时间迅速增加,并在24℃下约20分钟后达到平衡。较高浓度的[3H] AVM B1a导致显着更大的非特异性结合,在25nM时为60％。各种AVM类似物还在完整小脑神经元中产生[3H] AVM B1a结合的浓度依赖性抑制。 AVM B1a和莫昔克丁的效力相似(IC50值分别为120和126 nM)[3]。来自小鼠脑突触小泡的AVMB1a刺激的氯化物流出来自GABA不敏感的氯通道的激活,并且这种作用不同于它们先前记录的对小鼠脑制剂中GABA门控氯通道的影响[4]。
• 体内研究: 当AVM B1a浓度高于83.3 mg/kg时,细菌受到显着抑制,而真菌在土壤中受损较少。高浓度AVM B1a也抑制了土壤呼吸,这与土壤类型不同。 AVM B1a对土壤蚯蚓的半致死剂量(LD50)在滤纸接触试验中估计为4.63 mg×cm2,在人工土壤中处理7天和14天后分别为24.13和17.06 mg/kg [1]。在人工土壤中,AVM B1a对蚯蚓的LC50分别为24.1 mg/kg和17.1 mg/kg,持续7天和14天。在暴露于无AVM B1a土壤后1天内,两组中分别消除了约80.0％和94.8％的AVM B1a,但在蚯蚓相对较长时间内发现了痕量的AVM B1a [2]。 。
• 参考文献:

  [1]. Sun Y, et al. [Effects of avermectin B1a on soil microorganism and earthworm (Eisenia fetida)]. Ying Yong Sheng Tai Xue Bao. 2005 Nov;16(11):2140-3.

  [2]. Sun Y, et al. Bioaccumulation and elimination of avermectin B1a in the earthworms (Eisenia fetida). Chemosphere. 2005 Jul;60(5):699-704.

  [3]. Huang J, et al. Avermectin B1a binds to high- and low-affinity sites with dual effects on the gamma-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. J Pharmacol Exp Ther. 1997 Apr;281(1):261-6.

  [4]. Payne GT, et al. Activation of gamma-aminobutyric acid insensitive chloride channels in mouse brain synaptic vesicles by avermectin B1a. J Biochem Toxicol. 1991 Winter;6(4):283-92.

阿维菌素物理化学性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 940.9±65.0 °C at 760 mmHg
• 熔点: 157-162ºC
• 分子式: C₄₈H₇₂O₁₄
• 分子量: 873.077
• 闪点: 268.1±27.8 °C
• 精确质量: 872.492188
• PSA: 170.06000
• LogP: 6.51
• 外观性状: 白色结晶粉末
• 蒸汽压: 0.0±0.6 mmHg at 25°C
• 折射率: 1.571
• 储存条件: 通风低温干燥
• 计算化学:

  1.疏水参数计算参考值（XlogP）:3.8

  2.氢键供体数量:3

  3.氢键受体数量:14

  4.可旋转化学键数量:8

  5.互变异构体数量:无

  6.拓扑分子极性表面积:170

  7.重原子数量:62

  8.表面电荷:0

  9.复杂度:1730

  10.同位素原子数量:0

  11.确定原子立构中心数量:20

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:3

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

阿维菌素毒性和生态

阿维菌素安全信息

• 危险品运输编码: UN 2588
• 包装等级: II
• 危险类别: 6.1(a)
• 海关编码: 2932999099

阿维菌素海关

• 海关编码: 2932999099
• 中文概述: 2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
• 申报要素: 品名, 成分含量, 用途
• Summary: 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

阿维菌素英文别名

• 5-O-Demethyl Antibiotic C 076A1a
• Abamectinum [Latin]
• Abamectin B1a
• AVERMECTIN B1A
• (1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2S)-Butan-2-yl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-5,6-dihydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• Abamectine [French]
• [3H]-Abamectin B1a
• (1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2S)-2-Butanyl]-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-5,11',13',22'-tetramethyl-5,6-dihydro-2'H-spiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-2'-one
• (1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2S)-2-Butanyl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-5,6-dihydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• Abamectin komponente B1a
• 22,23-dihydroavermectinh B1a
• abamectin component B1a
• Avermectin B(1)a
• Abamectina [Spanish]
• (2aE,4E,5'S,6S,6'R,7S,8E,11R,13S,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-5',6,6',10,11,14,15,17,17a,20,20a,20b-dodecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• (2aE,4E,8E)-(5'S,6S,6'R,7S,11R,13S,15S,17aR,20R,20aR,20bS)-6'-((S)-sec-Butyl)-5',6,6',7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxospiro(11,15-methano-2H,13H,17H-furo(4,3,2-pq)(2,6)benzodioxacyclooctadecin-13,2'-(2H)pyran)-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• Vertimec(R)018SC
• Caswell No. 063AB
• (1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2S)-2-Butanyl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-5,6-dihydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1. 0]pentacosa[10,14,16,22]tetraen]-12'-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• (1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-6-[(2S)-2-Butanyl]-21',24'-dihydroxy-5,11',13',22'-tetramethyl-2'-oxo-5,6-dihydrospiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.1.0]pentacosa[10,14,16,22]tetraen]-12'-yl-2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranoside
• Antibiotic C 076B1a